Evidence map›Paper›PMID 41610433›Full record

ArticleJCI insight2026

Small noncoding RNA TY2 enhances efferocytosis and improves outcomes in a mouse model of sepsis.

Alessandra Ciullo, Xaviar M Jones, Hiroaki Komuro, Liang Li, Anh Nguyen, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessandra Ciullo
Xaviar M Jones
Hiroaki Komuro
Liang Li
Anh Nguyen
Eduardo Marbán
Ahmed Gamal-Eldin Ibrahim

Funding

Training in Advanced Heart Disease ResearchT32HL116273 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Joshua I Goldhaber, EDUARDO MARBAN · 2013 to 2026
$5.6M
Exosome-mediated cardioprotection and regenerationR01HL124074 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO · 2014 to 2021
$4.0M
Exosome Therapeutics to Dissect HFpEF MechanismsR01HL155346 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO, VAN EYK, JENNIFER E · 2021 to 2024
$3.3M
Macrophages as effectors of cell therapy for heart failureR01HL142579 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI IBRAHIM, AHMED · 2019 to 2023
$2.1M
Mechanisms of cardioprotective Y RNA signaling in macrophagesR01HL175335 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Ahmed Ibrahim · 2025 to 2026
$1.4M
NHLBI NIH HHS R01 HL124074NHLBI NIH HHS R01 HL142579NHLBI NIH HHS R01 HL155346NHLBI NIH HHS R01 HL175335NHLBI NIH HHS T32 HL116273
6 · The paper itself

Abstract

TY2 is a drug based on a natural compound with potent anti-inflammatory effects. TY2 improved outcomes in mice with severe bacterial infection.

Indexed as

Anti-Inflammatory AgentsEfferocytosisRNA, Small UntranslatedAnimalsDisease Models, AnimalHumansMacrophagesMicePhagocytosisAnti-Inflammatory AgentsRNA, Small UntranslatedCardiologyInflammationMacrophagesNoncoding RNAs

Identifiers

PMID41610433
PMCPMC13041665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.